Nitric Oxide Synthesis Enhances Human Immunodeficiency Virus Replication in Primary Human Macrophages

DONATIENNE BLOND, HERVÉ RAOUl, ROGER LE GRAND,* AND DOMINIQUE DORMONT

Service de Neurovirologie, Commissariat à l’Energie Atomique, DSV/DRM, CRSSA, Institut Paris-Sud sur les Cytokines, Fontenay aux Roses, France

Received 1 March 2000/Accepted 10 July 2000

Macrophages are suspected to play a major role in human immunodeficiency virus (HIV) infection pathogenesis, not only by their contribution to virus dissemination and persistence in the host but also through the dysregulation of immune functions. The production of NO, a highly reactive free radical, is thought to act as an important component of the host immune response in several viral infections. The aim of this study was to evaluate the effects of HIV type 1 (HIV-I) Ba-L replication on inducible nitric oxide synthase (iNOS) mRNA expression in primary cultures of human monocyte-derived macrophages (MDM) and then examine the effects of NO production on the level of HIV-I replication. Significant induction of the iNOS gene was observed in cultured MDM concomitantly with the peak of virus replication. However, this induction was not accompanied by a measurable production of NO, suggesting a weak synthesis of NO. Surprisingly, exposure to low concentrations of a NO-generating compound (sodium nitroprusside) and l-arginine, the natural substrate of iNOS, results in a significant increase in HIV-I replication. Accordingly, reduction of l-arginine bioavailability after addition of arginase to the medium significantly reduced HIV replication. The specific involvement of NO was further demonstrated by a dose-dependent inhibition of viral replication that was observed in infected macrophages exposed to N\textsuperscript{G}-monomethyl l-arginine and N\textsuperscript{G}-nitro-l-arginine methyl ester (L-NAME), two inhibitors of the iNOS. Moreover, an excess of l-arginine reversed the addition of L-NAME, confirming that an arginine-dependent mechanism is involved. Finally, inhibitory effects of hemoglobin which can trap free NO in culture supernatants and in biological fluids in vivo confirmed that endogenously produced NO could interfere with HIV replication in human macrophages.

The macrophage represents one of the major target cell for human immunodeficiency virus (HIV) infection and is likely to play a major role in persistence and tissue dissemination of this virus (35, 39). Macrophage immune functions are also altered by HIV type 1 (HIV-I) infection: (i) synthesis of inflammatory cytokines is dysregulated (8, 29, 94); (ii) in vitro-infected monocyte-derived macrophages (MDM) have decreased ability to act as accessory cells for T-lymphocyte proliferation (28); and (iii) the production of free radicals, such as hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}), superoxide anion (O\textsubscript{2}\textsuperscript{-}), and hydroxyl radicals (HO\textsuperscript{•}) (13, 74, 84), is impaired and may therefore facilitate the development of opportunistic intracellular pathogens. Among free radicals, NO is of particular interest. This molecule is generated by nitric oxide synthase (NOS) from L-arginine and rapidly reacts in vivo with oxygen to form nitrite and nitrate, its two stable end products (72, 76, 90). Three distinct isoforms of NOS have been described. Two are constitutive and mainly found in endothelial and neuronal cells (32, 53); the third, inducible NOS (iNOS), was originally described in murine macrophage (95). NO mediates numerous physiological functions and is known to be involved in several immunological disorders. Besides its participation to the relaxation of blood vessels and glutamate-induced neurotoxicity (11, 12, 49), the production of NO represents an important component of the host immune response against viral infections (20, 52, 67, 69) including retroviruses (Friend leukemia virus) (2). Antiviral effects occur through its microbiostatic and microbicidal activity, and probably also through its proinflammatory and immunoregulatory properties (33, 50, 71).

In some cases, the production of NO during infectious diseases may also be deleterious. This may be particularly true in HIV infection, where NO may contribute to AIDS pathogenesis: significant increases in nitrite and nitrate (the two stable end products of NO) concentrations were evidenced in peripheral blood mononuclear cells (PBMC), polymorphonuclear leukocytes, and sera of patients with AIDS, especially in individuals with neurological disorders and pulmonary disease caused by intracellular opportunistic pathogens (30, 92; D. Torre, G. Ferrari, G. Bonetta, C. Zeroli, M. Giola, and G. P. Fioli, Abstr. 10th Int. Conf. AIDS, Int. Conf. STD, abstr. PAn114, 1996). HIV-related neurological disorders could in part be attributed to excessive production of NO. Indeed, high concentrations of NO could be obtained in vitro (i) after direct interactions between viral components and neuronal cells, since gp120-induced injury in primary neuronal cultures involves NO (23, 24, 26), and (ii) after HIV-1 infection of macrophages infiltrating the brain tissue (55). Direct evidence for the presence and distribution of iNOS has been reported in human pulmonary tissue (54, 82) and in the central nervous system of HIV-infected patients, especially in areas of acute and chronic inflammation (1). The production of NO by human monocytes/macrophages could result from the induction of iNOS expression by the proinflammatory cytokines (21, 65, 77, 78, 85). Synthesis of these cytokines is induced in vivo and in vitro in response to HIV-1 infection (42, 89) and may directly regulate iNOS expression (15, 83). However, we cannot exclude that HIV-1 can also directly interact with iNOS expression in monocytes/macrophages. Indeed, viral regulatory proteins such as Tat may directly enhance the transcription of the iNOS.

Interestingly, Groeneveld et al. have shown that levels of nitrate in the serum are positively correlated with plasma and...
cell-associated virus loads, suggesting that HIV could induce NO synthesis in vivo (46). In the simian immunodeficiency virus/macaque model, significantly increased concentrations of NO\textsubscript{2} and NO\textsubscript{3} were measured in plasma during primary infection, coincident with viremia peaks, and in the absence of opportunistic infections (10).

The objectives of this study were to (i) evaluate the effects of HIV-1 infection on iNOS mRNA expression and NO production in cultured human MDM, (ii) assess whether the endogenous NO release interfere with HIV replication in cultured MDM, and (iii) study the mechanisms of NO regulation in response to MDM infection with primary HIV-1 isolates.

MATERIALS AND METHODS

Isolation and characterization of monocytes. Fresh human PBMC were obtained from healthy HIV-1-seronegative donors after centrifugation of heparinized venous blood over Ficoll-Hypaque gradients. Monocytes were isolated from PBMC by centrifugal elutriation (Beckman J2-21/ME centrifuge, JE-5 rotor; Beckman Instruments, Gagny, France) as previously described by Figdor et al. (31). Purified monocytes were cultivated at the concentration of 2 × 10\textsuperscript{6} cells/ml in 48-well microtiter plates and progressively allowed to differentiate into macrophages for 7 days in a 5% CO\textsubscript{2} atmosphere at 37°C. The culture medium was constituted of RPMI 1640 medium (Boehringer Mannheim, Mannheim, Germany) supplemented with 10% heat-inactivated fetal calf serum (Boehringer Mannheim), 2 mM glutamine (Boehringer Mannheim), and 0.2 mM L-arginine (penicillin-streptomycin-neomycin [Life Technologies, Inc., Berlin, Germany]). Immunophenotyping of the monocyte fraction was performed by standard fluorescence-activated cell sorter analysis as previously described (10), using a FACScan Plus cytometer and LYSSIS II software (Becton Dickinson, Mountain View, Calif.). Cellular purity was greater than 97%; these cells were negative for expression of CD3 (CD3 Leu4, immunoglobulin G1 [IgG1]; Becton Dickinson); and CD19 (CD19-fluorescin isothiocyanate [FITC]; IgG1; Immunotech, Martell, France) but positive for CD14 (CD14-FITC, IgG1; Becton Dickinson) and CD64 (CD64-FITC, IgG1; Medarex, West Lebanon, N.H.) expression (81.6 and 88.5%, respectively).

Infection of MDM and detection of virus replication. MDM were infected with macrophage-tropic HIV-1 reference strain Ba-L, a generous gift from A.-M. Aubertin (Institut Pasteur, Paris, France). This strain, initially obtained from a primary culture of postmortem lung tissue from an infant who died from AIDS (35, 36), replicates well in human macrophage cultures. HIV-1 Ba-L was grown to high titers in phlyohe-magglutinin-stimulated human bone marrow mononuclear cells. The cell-free supernatant was clarified at 10,000 × g for 5 min and ultracentrifuged at 360,000 × g (Beckman TL100; Beckman Instruments) for 10 min. The viral pellet was resuspended in PBS and used as a stock preparation. Applied Biosystems (Foster City, Calif.) was used to infect monocytes on nucleotide sequence. PCR products were purified with a USB US GS Plus reagent pack (Amersham Life Science, Cleveland, Ohio), using exonuclease I and shrimp alkaline phosphatase, before sequencing with a Dye Terminator Cycle Sequencing kit (Perkin-Elmer). The product was then loaded onto a 6% polyacrylamide gel in an automated laser fluorescent DNA sequencer (ABI model 377; Perkin-Elmer). Direct cycle sequencing was done with Taq DNA polymerase and antisense iNOS primers. DNA sequences were aligned and analyzed using the Sequencher program and GenBank (27). Specificity of the PCR was verified by using primers cross-hybridizing withhog iNOS (18S ribosomal) sequence (25). The cycle program for GAPDH amplification included denaturing at 94°C for 1 minute, annealing at 55°C for 1 minute, and extension at 72°C for 1 minute, for a total of 32 cycles. The iNOS cycle program included denaturation at 94°C for 1 minute, annealing at 55°C for 1 minute, and extension at 72°C for 2 minutes, for a total of 40 cycles. The optimal number of PCR cycles was determined by using a variable number of cycles to identify a linear range of amplification for each transcript. Eight-microliter aliquots of amplification mixtures were electrophoresed on a 10% agarose gel, and PCR products were detected by ethidium bromide staining.

Materials and reagents. PCR specificity was confirmed by determination of the primer extension. PCR products were purified with a USB 70095 reagent pack (Amersham Life Science, Cleveland, Ohio), using exonuclease I and shrimp alkaline phosphatase, before sequencing with a Dye Terminator Cycle Sequencing kit (Perkin-Elmer). The product was then loaded onto a 6% polyacrylamide gel in an automated laser fluorescent DNA sequencer (ABI model 377; Perkin-Elmer). Direct cycle sequencing was done with Taq DNA polymerase and antisense iNOS primers. DNA sequences were aligned and analyzed using the Sequencher program and GenBank (27). The presence of the signal was quantified using software (Image-Pro; developed by Wayne Rabasland, National Institutes of Health, Bethesda, Md.). Results were expressed, as previously published (16, 17), as the ratio of the signal obtained for each treated mRNA to the signal obtained for GAPDH mRNA.

Nucleotide sequence determination. PCR products were confirmed by determination of the primer extension sequence. PCR products were purified with a USB 70095 reagent pack (Amersham Life Science, Cleveland, Ohio), using exonuclease I and shrimp alkaline phosphatase, before sequencing with a Dye Terminator Cycle Sequencing kit (Perkin-Elmer). The product was then loaded onto a 6% polyacrylamide gel in an automated laser fluorescent DNA sequencer (ABI model 377; Perkin-Elmer). Direct cycle sequencing was done with Taq DNA polymerase and antisense iNOS primers. DNA sequences were aligned and analyzed using the Sequencher program and GenBank (27). The presence of the signal was quantified using software (Image-Pro; developed by Wayne Rabasland, National Institutes of Health, Bethesda, Md.). Results were expressed, as previously published (16, 17), as the ratio of the signal obtained for each treated mRNA to the signal obtained for GAPDH mRNA.

RNA extraction. At different culture time points, infected and noninfected MDM were scraped off and lysed in guanidinium isothiocyanate solution. Total cellular RNA was extracted as described by Chomczynski and Sacchi (18) by a phenol-chloroform method, precipitated in the presence of isopropanol at room temperature, and then washed twice in 75% ethanol. The RNA was resuspended in sterilized distilled water. The RNA concentration was determined by the absorbance at 260 nm.

Quantification of iNOS mRNA expression by RT-PCR. RT-PCR was performed using 10\textsuperscript{6} freshly isolated MDM for the quantification of mRNA expression. Total RNA was subjected to first-strand cDNA synthesis for 1 h at 42°C in a 20-μl reaction containing 0.25 M Tris-HCl (pH 8.3), 0.375 mM KCl, 15 mM MgCl\textsubscript{2}, 30 U of recombinant RNase inhibitor (Clontech, Palo Alto, Calif.), 30 μM each dNTP, 0.2 μg of oligo(dT)\textsubscript{12-18} (Sigma), and 150 U of Moloney murine leukemia virus RT (GIBCO-BRL, Grand Island, N.Y.). After completion of first-strand synthesis, the reaction mixture was diluted to 160 μl. Five microliters of this dilution was used for each PCR. The PCR mixture (in a volume of 50 μl) contained a 10 μM each dNTP, 100 ng of each specific primer, buffer as supplied by manufacturer, and 0.5 μg of Taq polymerase (ATGC Biotechnology, Noisy le Grand, France). Sequences of primers specific for iNOS (19, 64, 66) were as follows: iNOS-5'–5'TCCAGGAAAAAGACGACATTCGA; iNOS-3', 5'-GGGTTGGGTTGGTTGGTGTATGG; GAPDH-5', 5'-ACCACTATGGAAAGAAGCTTG; and GAPDH-3', 5'-CTAA GTGCTGATCCACAGATG. Amplification products were visualized by ethidium bromide staining.
Effects of iNOS inhibitors on HIV-1 replication in human macrophages. Two specific competitive inhibitors of iNOS, L-NMMA and L-NAME, represent powerful tools to confirm that endogenous production of NO modulates viral replication (25, 41, 43, 51). Twenty-four hours after HIV infection, MDM were treated with one of the two inhibitors at doses ranging from 0.1 to 1 mM. These components were maintained at constant concentrations in the culture medium throughout the postinfection period. L-NMMA significantly reduced, in a dose-dependent manner, the replication of HIV-1 Ba-L in MDM; this was statistically significant for two different donors tested. Addition of 1 mM L-arginine had no marked effect on viral replication (Fig. 4).

As a reciprocal control, arginase was used to deplete L-arginine in the culture medium. This enzyme has potential implication in AIDS pathogenesis since abnormal concentrations could be identified in patient fluids. A dose-dependent inhibition of HIV replication was observed in the MDM cultures maintained in the presence of arginase (1 to 20 U/ml) (Fig. 5) with no significant decrease of cellular viability. At the dose of 10 U/ml, arginase significantly reduces the replication of HIV-1 by treating MDM with NaNO2, with doses ranging between 0.1 and 10 μM (data not shown).

FIG. 1. Effects of HIV-1 Ba-L replication on iNOS mRNA transcription and NO2− production in human MDM cultures. (A) Level of HIV replication determined by the measure of RT activity in culture supernatants (mean of three independent culture wells ± SD); ○, RT activity in uninfected controls (mean of three independent culture wells ± SD); ●, production of nitrites in culture supernatants of infected macrophages (mean of three independent culture wells ± SD); □, nitrite production in uninfected control cultures (mean of three independent culture wells ± SD). (B) Expression of iNOS mRNA in the same culture of infected, or uninfected macrophages, determined as the ratio of the signal obtained for tested mRNA to the signal obtained for GAPDH mRNA (mean of two independent culture wells). Bars represent the mean of two independent measures.

centrifugal elutriation were allowed to differentiate into MDM, without granulocyte-macrophage colony-stimulating factor stimulation, for 7 days before infection with HIV-1 Ba-L. The RT activity measured in culture supernatants peaked between days 15 and 21 (Fig. 1). As observed in Fig. 1, a significant induction of iNOS gene expression occurred at the time of viral replication peak (Fig. 1B). However, this was not associated with the production of detectable amounts of nitrites in culture supernatants (Fig. 1A).

Effects of NO-generating compounds on HIV-1 replication in MDM. As reported by Bukrinsky et al. (14, 15), low expression of iNOS may lead to low production of nitrites remaining undetectable by the Griess assay, the sensitivity of which is approximately 250 nM. We therefore designed an experimental approach to determine whether low levels of NO released in culture supernatants could modulate HIV replication in MDM. HIV-1 Ba-L-infected MDM were treated with low concentrations of NO donors such as SNP, which is a classically used NO-generating compound (6, 37, 61, 70, 88). Doses of SNP that we used were reported by others to be efficient in human cell cultures (27, 60, 70) and appeared to be suitable for the in vivo situation, consistent with the levels of NO detected in plasma of asymptomatic seropositive patients (5, 62, 92). We verified that in our model, NO2− was generated from SNP in a dose-dependent manner (data not shown). A sequential and time-dependent release of nitrite was consistently obtained at the dose of 10 μM. Therefore, 24 h after HIV infection, MDM were treated with SNP at doses ranging from 0.1 to 10 μM. Concentration in the culture medium was maintained constant throughout the postinfection period. As control, HIV-1 Ba-L-infected MDM were treated with identical concentrations of KPC, a compound that is very similar in chemical structure to SNP but does not generate free NO in culture supernatants.

Unexpectedly, treatment at lower SNP concentrations, 0.1 and 1 μM, resulted in a significant increase of viral replication in MDM cultures (Fig. 2A). This was confirmed in cultures of MDM obtained from three out of the four tested donors (Fig. 3). At a higher concentration of SNP, 10 μM, HIV-1 replication in MDM was inhibited (Fig. 3) as previously reported (68). NO generated by SNP in culture medium is naturally and rapidly reduced in nitrite (NO2−). We verified that NO2− was not, by itself, responsible for the increased replication of HIV-1 by treating MDM with NaNO2, with doses ranging between 0.1 and 10 μM (data not shown).

1-Arginine causes a dose-dependent enhancement of HIV-1 replication in human macrophages. 1-Arginine is the natural substrate of iNOS. In this experiment, MDM were cultured in the presence of different doses of 1-arginine, ranging from 0.1 to 1 mM, previously reported by Belenky et al. (7) to modulate NO synthesis in cultured macrophages. These doses did not appear to affect MDM viability (data not shown). Low concentrations of 1-arginine (0.1 and 0.5 mM) appeared to enhance replication of HIV-1 Ba-L in MDM; this was statistically significant for two different donors tested. Addition of 1 mM 1-arginine had no marked effect on viral replication (Fig. 4).

As a reciprocal control, arginase was used to deplete 1-arginine in the culture medium. This enzyme has potential implication in AIDS pathogenesis since abnormal concentrations could be identified in patient fluids. A dose-dependent inhibition of HIV replication was observed in the MDM cultures maintained in the presence of arginase (1 to 20 U/ml) (Fig. 5) with no significant decrease of cellular viability. At the dose of 10 U/ml, arginase significantly reduces the replication of HIV (P < 0.05).

Effect of iNOS inhibitors on HIV-1 replication in human macrophages. Two specific competitive inhibitors of iNOS, L-NMMA and L-NAME, represent powerful tools to confirm that endogenous production of NO modulates viral replication (25, 41, 43, 51). Twenty-four hours after HIV infection, MDM were treated with one of the two inhibitors at doses ranging from 0.1 to 1 mM. These components were maintained at constant concentrations in the culture medium throughout the postinfection period. L-NMMA significantly reduced, in a dose-dependent manner, the replication of HIV-1 Ba-L (Fig. 6A). Moreover, treatment of infected MDM with equal molar concentrations of 1-NMMA, an inactive enantiomer of L-NMMA, had no significant effect on HIV-1 replication (Fig.
M are needed to affect MDM viability (data not shown). In our culture system, Hb concentrations above 200 have been observed. This confirms the data reported by others that concentration, no toxic effects of Hb on cultured MDM the viral replication in HIV-1 Ba-L-infected MDM (Fig. 8). At We observed that 0.5 activity (91) by trapping NO produced in culture medium (40).

of Hb in culture supernatants mainly affects extracellular NO release of tumor necrosis factor alpha (TNF-α) (97). Addition of L-NAME in a dose-dependent manner (Fig. 7), confirming the major mechanism of NO activity (57). The biological activity of NO could be abolished in vivo by Hb, which oxidizes NO to nitrate (48). Zinetti et al. have reported that monocyte hyperactivation by lipopolysaccharide could be affected by Hb and L-NMMA, through the modulation of the NO-dependent release of tumor necrosis factor alpha (TNF-α) (97). Addition of Hb in culture supernatants mainly affects extracellular NO activity (91) by trapping NO produced in culture medium (40). We observed that 0.5 μM Hb is able to significantly decrease the viral replication in HIV-1 Ba-L-infected MDM (Fig. 8). At that concentration, no toxic effects of Hb on cultured MDM have been observed. This confirms the data reported by others (14, 70). In our culture system, Hb concentrations above 200 μM are needed to affect MDM viability (data not shown).

**DISCUSSION**

The aim of this study was to determine the relationships between the production of NO and modulation of HIV-1 replication in human macrophages. We first observed that iNOS expression is induced in primary human macrophage cultures during infection in vitro with the macrophagetropic HIV-1 Ba-L. Conflicting reports have been published regarding the expression of an iNOS gene in human macrophages; nevertheless, the increase that we observed confirms the results found by Bukrinsky et al. in HIV-infected cultures (15). Despite a significant induction of iNOS expression, we did not succeed, as others have previously reported (15), in detecting any nitrite production in culture supernatants. This observation is nevertheless in agreement with results of Padgett and Pruett (79), who also detected no nitrite production after activation of human macrophages with lipopolysaccharide, gamma interferon, phorbol myristate acetate, or opsonized zymosan. However, we cannot exclude that this discrepancy may also be attributable in part to the low sensitivity of the Griess reaction, which is estimated to be approximately 250 nM (15, 73, 83).

In vivo, there is convincing evidence that human macrophages may synthesize detectable NO during HIV infection. In plasma, the nitrate and nitrite concentrations correlate with levels of neopterin, a marker of activation of mononuclear phagocytes (34). Increased production of NO was evidenced in PBMC of AIDS patients, in particular in individuals with opportunistic infections. Asymptomatic seropositive patients exhibited low production of NO (<1 μM).

The detection of iNOS expression that we observed, without any substantial accumulation of nitrite, suggested that NO could be released at low levels after HIV-1 infection. We therefore investigated the direct effects of low concentrations of NO on HIV-1 replication in MDM. The release of this unstable free radical in culture was obtained by using SNP, an exogenous NO donor. Interestingly, treatment of MDM with low doses of SNP enhanced viral replication, indicating that NO may interfere with viral replication mechanisms. This interaction could be directly mediated by NO but may also result from indirect mechanisms related, for instance, to macrophage activation (14, 15, 60). Indeed, very low doses of NO (<1 μM) could enhance soluble guanylate cyclase and GTPase activities, two markers of macrophage activation.

The observation that the modulation of NO synthesis by infected macrophages, using L-arginine, iNOS inhibitors, Hb, and arginase, modulates in the same direction the replication of HIV in MDM argues for a pivotal role of NO in the induction of this phenomenon. The specific involvement of the iNOS pathway in our experimental model was further demonstrated by the dose-dependent inhibition of viral replication in the presence of specific NOS inhibitors.

In summary, the effects of L-NMMA, L-NAME, and arginase on the infected macrophage cultures show that NO can influence the viral replication through an inducible L-arginine-dependent pathway, which is in accordance with previous report (14). While it is possible that human macrophages may be stimulated to produce reactive nitrogen intermediate by cytokines and/or pathogens, our results confirm that the specific L-arginine-dependent mechanism could be also modulated in turn, by HIV replication in human macrophage cultures as described elsewhere (25, 38). This is potentially important, since it contrasts sharply with the well-established antimicrobial and antiviral properties of NO. The unusual low produc-

![FIG. 2. Effects of NO-generating compounds on HIV-1 replication in MDM. Purified monocytes from PBMC were cultured for 7 days in 24-well microtiter plates and then infected with HIV-1 Ba-L. Culture supernatant was completed removed every 2 or 3 days and replaced by fresh culture medium. HIV replication in macrophages was determined by the mean level of RT (±SD) activity in culture supernatants of three independent wells. The x axis indicates the time points of medium exchange. (A) Replication of HIV in infected macrophages treated or not with SNP; (B) effect of the KPC control on HIV replication in macrophages.](http://jvi.asm.org/)
tion of NO by HIV-infected human monocytes could probably explain the lack of antiviral activity. However, these low concentrations could be sufficient to affect the biology of MDM, resulting in enhanced HIV-1 replication.

The molecular mechanisms involved in the induction of NO production in HIV-infected MDM remain unclear. We can postulate that iNOS mRNA expression may result from direct interactions between virus and resident macrophages. Pi- etraforte et al. (83) reported that recombinant HIV envelope glycoprotein gp120 stimulates a very low production of NO by human MDM. Enhanced replication of HIV may also involve the activation of NF-κB, which is a cellular component regulating HIV replication and also the expression of several cytokines (4, 75). Indeed, NO induces the production of TNF-α, which may in turn activate viral replication in MDM (63, 64). Previous findings concerning the modulation of NF-κB activation by NO are controversial. An early study indicates that chemical NO donors (SNP and SNAP) are able to activate NF-κB in human peripheral blood mononuclear cells. Lander et al. (61) have reported that production of nitric oxide radicals activates the NF-κB transcription factor in doses within the range of those used in our experiments (68, 80). In our experiments, partial inhibition of HIV needs 10- to 100-times-higher concentrations of SNP to decrease activation of NF-κB. However, such high NO concentrations do not reflect the production of NO observed in vivo in human fluids (5, 30, 92, 96; Torre et al., Abstr. 10th Int. Conf. AIDS, 1996).
Primary targets of reactive nitrogen oxide species may be different in cells submitted to low (<1 μM) or steady-state concentrations of NO. An explanation for these conflicting results might be related to the different fluxes of NO used in these experiments. Indeed, Lander et al. found that micromolar or submicromolar concentrations of pharmacological sources of NO were sufficient to activate NF-κB via an enhancement of GTPase activity (58–60). In other reports, inhibitory concentrations of NO donors were frequently 100 times higher than micromolar amounts shown to activate NF-κB per se (68, 81). Therefore, it may be that low amounts of NO would activate NF-κB, whereas high fluxes of NO would be inhibitory. This hypothesis is reinforced by biphasic effects of NO on GTPase activity, which is inhibited by high concentrations of NO (58).

In the same way, the tendency to decrease HIV-1 replication that was observed with higher concentrations of L-arginine (1 mM) could be due to a negative feedback exerted by NO on NOS activity as previously described (3, 45, 87).

AIDS is associated with activation of the immune system. Correlations of nitrite and nitrate with the immune activation markers (sTNFR 55 and TNFR 75) and neopterin in HIV-1-infected patients (96) suggest that endogenous cytokines, like TNF-α, could activate inflammatory cells (44). This additional priming could be sufficient to amplify the induction of iNOS and increase NO production by the infected macrophage (10). The increased production of cytokines and NO may in turn contribute to the immunopathogenesis of HIV disease both by enhancing HIV replication and by direct effects on target tissues, such as the brain and lung.

The impact of NO production on HIV-1 infection is still difficult to predict. Our results suggest that NO, in vivo, may...
favors virus replication in MDM rather than exert an efficient antiviral activity. Nevertheless, considerable controversy remains regarding the ability of human macrophages to generate biologically significant amounts of NO, and it is not clearly established whether an elevated nitrite level in serum or tissues of HIV-infected patients is a cause, effect, or epiphenomenon of HIV-1 infection. However, Torre et al. have shown that HIV-1 stimulates NO production by human macrophages and that the NO concentration is increased in the sera of patients with AIDS, especially in those with neurological disorders and pulmonary disease caused by intracellular opportunistic pathogens (Torre et al., Abstr. 10th Int. Conf. AIDS, 1996). Moreover, Groeneveld et al. have demonstrated that serum nitrate in such patients correlates positively with viral load, strongly suggesting that our in vitro observations may be relevant for in vivo situations and thus should be considered with special attention for the design of new therapeutic strategies (46). In addition, the significant increased concentrations of NO$_2^-$ and NO$_3^-$ observed in the plasma of patients during primary simian immunodeficiency virus infection (10) seems to be closely related to active virus production. Peaks of NO$_3^-$ in plasma and p27 antigenemia were detected simultaneously in the absence of any opportunistic infections, suggesting that NO production may therefore contribute to virus-induced pathogenesis as early as the first days following infection.

ACKNOWLEDGMENTS

We thank L. Minghetti for helpful discussions and for critical reading of the manuscript. We acknowledge the Centre de Cytaphérèse de l’Hôpital Saint-Louis (Paris, France) for technical assistance. We thank Dominique Marcé for technical support.

This work was supported by the Agence Nationale de Recherches sur le SIDA (ANRS; Paris, France), Centre de Recherches du Service de Santé des Armées (CRSSA; La Tronche, France), Commissariat à l’Énergie Atomique (CEA; Fontenay aux Roses, France), and Institut Paris-Sud sur les Cytokines (IPSC) and Tous ensemble contre le SIDA (SIDACTION) (Paris, France).

REFERENCES


14. Bukinsky, M., H. Schmidmayerova, G. Zabarh, L. Dubrowsky, B. Sherry,

FIG. 7. Reversion of the effect of the inhibitor L-NAME on HIV-1 replication in human macrophages by the addition of arginine. HIV replication is represented by the sum, at the end of the culture of an individual well, of the RT activities of each time point of medium exchange (every 2 or 3 days). Bars indicate the mean (±SD) of RT activity of three independent wells. Statistical analysis was performed using the nonparametric Mann-Whitney U test. *, significant differences between treated and untreated HIV-infected cultures (P < 0.05).


